Xintela (XINT) Q1 2026 earnings summary

Executive summary

• Achieved primary objective in Phase I/IIa clinical study of XSTEM for hard-to-heal venous leg ulcers, confirming safety and tolerability.

• Expanded patent portfolio with new grants in the US (wound healing) and Japan (ARDS), strengthening commercialization prospects.

• EQSTEM publication on osteoarthritis in horses received a scientific award, supporting disease-modifying claims.

• Ongoing revenue from GMP collaborations and new board appointments to support strategic growth.

Financial highlights

• Net sales for Q1 2026 were TSEK 443, up from TSEK 140 in Q1 2025.

• Group operating loss for Q1 2026 was TSEK -11,205, compared to TSEK -10,094 in Q1 2025.

• Loss before tax for Q1 2026 was TSEK -11,780, versus TSEK -10,661 year-over-year.

• Cash and cash equivalents at March 31, 2026, were TSEK 9,783, up from TSEK 6,398 a year earlier.

• Cash flow for Q1 2026 was TSEK -12,932, compared to TSEK -10,214 in Q1 2025.

Outlook and guidance

• Strategy focuses on establishing partnerships and commercial collaborations for XSTEM in osteoarthritis and wound healing.

• Evaluating early market introduction of XSTEM in select markets based on existing clinical data.

• Continued efforts to secure financing and strengthen business development capabilities.